TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03439722

Intervention type: OTHER
Intervention: Polysomnography
Description: Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
Study: NCT01833910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHA CPR Anytime Video Self-Instruction Kit
Description: CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHA CPR Anytime DVD
Description: A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHA CPR Anytime DVD
Description: A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHA CPR Anytime DVD
Description: A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
Study: NCT04211792

Intervention type: DEVICE
Intervention: Icare Tonometer
Description: Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
Study: NCT00684710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ-417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02700620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Guided internet treatment
Study: NCT00811291

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamine-B and Folic Acid Complex, calcium
Description: 90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Description: according to protocol
Study: NCT04147208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state
Study: NCT01369667

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02717429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
Study: NCT04788485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmectite
Description: use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmectite
Description: use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
Study: NCT04147208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: Administered orally ETV 0.5 mg once daily in fasted state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV
Description: Administered orally ETV 0.5 mg once daily in fasted state
Study: NCT01238874

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Cardiac Resynchronization Therapy
Description: All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
Study: NCT02136329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc
Study: NCT04221659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
Study: NCT01784328

Intervention type: DEVICE
Group type: OTHER
Intervention: Peristeen Bowel Irrigation System
Description: A complete system for bowel Irrigation to manage bowel dysfunction
Study: NCT03194659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
Study: NCT02189772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine extended release
Description: MG01CI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive drug
Study: NCT00550615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib Maximum Tolerated Dose
Description: An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
Study: NCT04111926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
Study: NCT00641745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: 40 - 120mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone
Study: NCT01950364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin and rifampicin
Description: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
Study: NCT03583502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: krill oil and fish oil supplement
Description: Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
Study: NCT04474392

Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: Observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: Observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: Observational study, no intervention will be administered.
Study: NCT02411006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prediction mailing
Description: Ask people to predict their upcoming medication adherence
Study: NCT01059344

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesalamin
Description: 4.8g/day, 800 mg tablets
Study: NCT03339167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic availability of lysine in millet
Description: Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
Study: NCT03730818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-based Exercise Group
Description: The intervention consist will of a water-based exercise protocol
Study: NCT03672812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: liraglutide 3mg 6/6 hours
Study: NCT05076773

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided block
Description: Giving one regional block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided block
Description: Giving one regional block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided block
Description: Giving one regional block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV morphine
Description: given when VAS\>3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: given when VAS\>3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: given when VAS\>3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: given when VAS\>3
Study: NCT00648388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol Tablets 100 mg
Description: 100mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal® Tablets 100 mg
Description: 100 single dose fasting
Study: NCT04538118

Intervention type: BEHAVIORAL
Intervention: Shoulder disability
Description: Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.

Intervention type: DEVICE
Intervention: Shoulder Range of Motion
Description: Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.

Intervention type: BEHAVIORAL
Intervention: Pain Intensity
Description: Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.
Study: NCT03800537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
Study: NCT03116035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based decision aid
Description: Patients were randomized to receive links to a commercially available decision aid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard websites
Description: Patients were randomized to receive links to standard, high-quality websites.
Study: NCT01006655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate HFA
Description: 100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inhalation twice a day for one month, preceded and followed by adenosine challenge test
Study: NCT00613327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride OROS
Description: Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
Study: NCT03160248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
Study: NCT03727022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Study: NCT03851887

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAI combine SBRT
Description: TAI combine SBRT
Study: NCT03203824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dark chocolate
Description: Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non dark chocolate
Description: No dark chocolate will be given to this group during the procedures.
Study: NCT03828097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental supplement
Description: Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
Study: NCT01674049

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Nutrition
Description: Nutritional supplement consumed either immediately following a 40min resistance exercise bout

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition 3 hours Post-Bout
Description: Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: A single 40 minute circuit-style bout of resistance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: A single 40 minute circuit-style bout of resistance exercise
Study: NCT03652363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glial cell line-derived neurotrophic factor
Description: Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glial cell line-derived neurotrophic factor
Description: Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
Study: NCT00395486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10mg
Study: NCT00683930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 2 g/Day
Description: Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) 3 g/Day
Description: Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
Study: NCT03628105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR Before Exposure
Description: Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR After Exposure
Description: Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
Study: NCT01145001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects
Study: NCT02411006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prediction mailing
Description: Ask people to predict their upcoming medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment mailing
Description: Ask people to commit to their upcoming medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment mailing
Description: Ask people to commit to their upcoming medication adherence
Study: NCT02593149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearGuard HD End Cap
Description: The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub